Health Care [ 6/12 ] | Biotechnology [ 43/75 ]
NASDAQ | Common Stock
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation.
The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.
Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -1.16 Decreased by -38.10% | -1.02 Decreased by -13.73% |
| Aug 12, 25 | -1.03 Decreased by -19.77% | -1.04 Increased by +0.96% |
| May 13, 25 | -1.09 Decreased by -32.93% | -0.87 Decreased by -24.69% |
| Mar 26, 25 | -0.84 Increased by +25.66% | -0.86 Increased by +2.78% |
| Nov 12, 24 | -0.84 Increased by +11.58% | -0.90 Increased by +6.67% |
| Aug 14, 24 | -0.86 Increased by +43.79% | -0.87 Increased by +1.15% |
| May 15, 24 | -0.82 Increased by +39.26% | -1.07 Increased by +23.36% |
| Mar 28, 24 | -1.13 Increased by +16.30% | -0.77 Decreased by -46.75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -61.46 M Decreased by -39.85% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -54.31 M Decreased by -20.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -57.46 M Decreased by -33.51% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 26.65 M Increased by +N/A% | -44.10 M Increased by +25.89% | Decreased by -165.47% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -43.95 M Increased by +12.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -45.12 M Increased by +43.74% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -43.04 M Increased by +39.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -59.52 M Increased by +15.52% | Decreased by N/A% Decreased by N/A% |